Canaccord analyst William Plovanic lowered the firm’s price target on Tandem Diabetes (TNDM) to $24 from $59 and keeps a Buy rating on the shares. The firm said its Q2 total company revenue beat consensus, and more importantly, US pump revenue missed estimates. Further, the company reframed its total revenue guidance, but lowered US and raised OUS revenues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes downgraded to Hold from Buy at Nephron Research
- Tandem Diabetes price target lowered to $13 from $20 at Wells Fargo
- Tandem Diabetes downgraded to Neutral from Overweight at Piper Sandler
- Tandem Diabetes Care Reports Record Q2 2025 Sales
- Tandem Diabetes Care: Strong Revenue Performance and Promising Portfolio Justify Buy Rating Despite Challenges